MISSIONThe EF Clif is intended to support high quality research and education on Acute-on-Chronic Liver Failure (ACLF), in order to improve the quality of life and to increase the survival of patients with liver cirrhosis.
VISIONOur aim is helping investigators to achieve their objectives and being a referent in ACLF research, in order to increase survival of patients with liver cirrhosis and improve their quality of life.
SERVICE INNOVATION HEALTH RESEARCH UNITY EDUCATION COMPROMISEQUALITY OF LIFEDEDICATION ACCURACY WELFARE DYNAMISM TRANSPARENCY COMMITMENT INDEPENDENCE
FACTS AND FIGURES
1,000
MORE THAN 1,000 INVESTIGATORS WORKING ON EF Clif SPONSORED SCIENTIFIC PROJECTS, FUNDED WITH MORE THAN
7,000,000 €/ year
236
CENTRES
44
COUNTRIES
Collaborators in Europe, North America, South America, Asia and Oceania 236 centres distributed in 3 international networks, in 44 countries around the world.
114
104
25
NUMBER OF CENTRES
EASL - CLIF
ACLARA
ENTR
799
217
56
COLLABO- RATORS
EASL - CLIF
ACLARA
ENTR
42%EASL-CLIF
339
44%ACLARA
96
45%ENTR
25
58%EASL-CLIF
460
56%ACLARA
121
55%ENTR
31
Number of countries involved in the EF Clif projects in each of the continents
2NORTH AMERICA
28EUROPE
5ASIA
7LATIN AMERICA
2OCEANIA
International networks
EASL-CLIF Consortium: Europe
ENTR-European Network for Translational Research: Europe and North America
Global Projects: Asia, Europe, North America, Latin America, Oceania
PATIENT COHORTS IN THE EF Clif STUDIES
PARTICIPATING HOSPITALS
RECRUITED PATIENTS
SAMPLES
ALIQUOTES
CANONIC
PREDICT
ACLARA
MICROB-PREDICT
DECISION
*Expected
2020 MILESTONES
MARCH
The recruitment of the ACLARA Study is completed
MAY
The REP-COVID Study is launched to collaborate in the search of a cure for the SARS-CoV-2 infection
JULY
The EASL Clif Consortium reached it’s highest number of partners: 114
FEBRUARY
Prof Rajiv Jalan was appointed as the Scientific Director of the EF Clif
MARCH
The recruitment of the ACLARA Study is completed
APRIL
Kick off of the DECISION Project, the new H2020 Adventure
MAY
The REP-COVID Study is launched to collaborate in the search of a cure for the SARS-CoV-2 infection
MAY
The New England Journal of Medicine publishes an outstanding review article signed by Vicente Arroyo, Richard Moreau and Rajiv Jalan with the most recent findings in ACLF
JULY
The EASL Clif Consortium reached it’s highest number of partners: 114
NOVEMBER
The EF Clif collaborates with the most relevant international liver transplant societies, the ILTS and the ELITA, to sponsor and launch the CHANCE Study, the first worldwide study on survival of liver transplantation in patients with ACLF